[1]GHAZARIAN A A, KELLY S P, ALTEKRUSE S F, et
al. Future of testicular germ cell tumor incidence in the United
States: Forecast through 2026 [J]. Cancer, 2017, 123(12):
2320-8.
[2]BUCHER-JOHANNESSEN C, PAGE C M,
HAUGEN T B, et al. Cisplatin treatment of testicular cancer
patients introduces long-term changes in the epigenome [J].
Clinical epigenetics, 2019, 11(1): 179.
[3]KVAMMEN Ø, MYKLEBUST T Å, SOLBERG A, et
al. Long-term Relative Survival after Diagnosis of Testicular
Germ Cell Tumor [J]. Cancer Epidemiology, Biomarkers &
Prevention, 2016, 25(5): 773-9.
[4]GAYER F A, FICHTNER A, LEGLER T J, et al. A
Coculture Model Mimicking the Tumor Microenvironment
Unveils Mutual Interactions between Immune Cell Subtypes
and the Human Seminoma Cell Line TCam-2 [J]. Cells, 2022,
11(5).
[5]FANKHAUSER C D, CURIONI-FONTECEDRO A,
ALLMANN V, et al. Frequent PD-L1 expression in testicular
germ cell tumors [J]. British journal of cancer, 2015, 113(3):
411-3.
[6]ZSCHäBITZ S, LASITSCHKA F, JäGER D, et
al. Activity of immune checkpoint inhibition in platinum
refractory germ-cell tumors [J]. Annals of Oncology, 2016,
27(7): 1356-60.
[7]YESTE-VELASCO M, GUO T, MAO X, et al. The
potential of brentuximab vedotin, alone or in combination
with current clinical therapies, in the treatment of testicular
germ cell tumors [J]. American journal of cancer research,
2019, 9(5): 855-71.
[ 8 ] L A N G F, S C H R ö R S B , L ö W E R M , e t a l .
Identification of neoantigens for individualized therapeutic
cancer vaccines [J]. Nature Reviews Drug Discovery, 2022,
21(4): 261-82.
[9]MACKENSEN A, HAANEN J B A G, KOENECKE
C, et al. LBA38 BNT211-01: A phase I trial to evaluate safety
and efficacy of CLDN6 CAR T cells and CLDN6-encoding
mRNA vaccine-mediated in vivo expansion in patients with
CLDN6-positive advanced solid tumours [J]. Annals of
Oncology, 2022, 33: S1404-S5.
[10]MENG J, GAO J, LI X, et al. TIMEAS, a promising
method for the stratification of testicular germ cell tumor
patients with distinct immune microenvironment, clinical
outcome and sensitivity to frontline therapies [J]. Cellular
Oncology, 2023, 46(3): 745-59.